Eris Lifesciences Limited (ERIS.BO)
INR 1492.1
(4.15%)
INR 1492.1
(4.15%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 10.42 Billion INR | -20.09% |
| 2022 | 13.04 Billion INR | 22.47% |
| 2021 | 10.65 Billion INR | 12.05% |
| 2020 | 9.5 Billion INR | 8.11% |
| 2019 | 8.79 Billion INR | 8.3% |
| 2018 | 8.12 Billion INR | 17.54% |
| 2017 | 6.9 Billion INR | 7.55% |
| 2016 | 6.42 Billion INR | 29.4% |
| 2015 | 4.96 Billion INR | 10.47% |
| 2014 | 4.49 Billion INR | 10.02% |
| 2013 | 4.08 Billion INR | 28.43% |
| 2012 | 3.18 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 5.52 Billion INR | 5.51% |
| 2024 Q1 | 3.3 Billion INR | 19.61% |
| 2023 Q2 | 4.05 Billion INR | 6.36% |
| 2023 Q4 | 2.76 Billion INR | -29.97% |
| 2023 FY | 10.42 Billion INR | -20.09% |
| 2023 Q1 | 3.81 Billion INR | 19.59% |
| 2023 Q3 | 3.94 Billion INR | -2.79% |
| 2022 Q4 | 3.19 Billion INR | -3.02% |
| 2022 FY | 13.04 Billion INR | 22.47% |
| 2022 Q3 | 3.29 Billion INR | -5.88% |
| 2022 Q2 | 3.49 Billion INR | 13.89% |
| 2022 Q1 | 3.06 Billion INR | 29.51% |
| 2021 Q1 | 2.74 Billion INR | 30.71% |
| 2021 Q3 | 2.66 Billion INR | -7.08% |
| 2021 FY | 10.65 Billion INR | 12.05% |
| 2021 Q2 | 2.86 Billion INR | 4.42% |
| 2021 Q4 | 2.37 Billion INR | -11.11% |
| 2020 Q4 | 2.1 Billion INR | -15.44% |
| 2020 Q1 | 2.3 Billion INR | 15.38% |
| 2020 Q2 | 2.61 Billion INR | 13.42% |
| 2020 Q3 | 2.48 Billion INR | -4.91% |
| 2020 FY | 9.5 Billion INR | 8.11% |
| 2019 Q3 | 2.18 Billion INR | -6.73% |
| 2019 FY | 8.79 Billion INR | 8.3% |
| 2019 Q4 | 1.99 Billion INR | -8.75% |
| 2019 Q2 | 2.34 Billion INR | 3.87% |
| 2019 Q1 | 2.25 Billion INR | 29.31% |
| 2018 Q3 | 2.09 Billion INR | -4.96% |
| 2018 FY | 8.12 Billion INR | 17.54% |
| 2018 Q4 | 1.74 Billion INR | -16.42% |
| 2018 Q2 | 2.19 Billion INR | 5.66% |
| 2018 Q1 | 2.08 Billion INR | 17.58% |
| 2017 Q4 | 1.77 Billion INR | 1.85% |
| 2017 FY | 6.9 Billion INR | 7.55% |
| 2017 Q1 | 1.57 Billion INR | 22.57% |
| 2017 Q2 | 1.9 Billion INR | 20.88% |
| 2017 Q3 | 1.73 Billion INR | -8.83% |
| 2016 Q3 | 1.62 Billion INR | -7.53% |
| 2016 FY | 6.42 Billion INR | 29.4% |
| 2016 Q4 | 1.28 Billion INR | -20.73% |
| 2016 Q2 | 1.75 Billion INR | 15.9% |
| 2016 Q1 | 1.51 Billion INR | 0.0% |
| 2015 FY | 4.96 Billion INR | 10.47% |
| 2014 FY | 4.49 Billion INR | 10.02% |
| 2013 FY | 4.08 Billion INR | 28.43% |
| 2012 FY | 3.18 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alkem Laboratories Limited | 52.29 Billion INR | 80.062% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -569.873% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 61.066% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | -67.561% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 93.259% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -71415.806% |
| FDC Limited | 8.33 Billion INR | -25.1% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 16.136% |
| Ipca Laboratories Limited | 29.8 Billion INR | 65.022% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -1497.755% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -5310.135% |
| Laurus Labs Limited | 24.62 Billion INR | 57.649% |
| Lupin Limited | 123.71 Billion INR | 91.572% |
| Medicamen Biotech Limited | 495.49 Million INR | -2004.318% |
| Medico Remedies Limited | 262.14 Million INR | -3877.505% |
| Megasoft Limited | 342.07 Million INR | -2948.136% |
| NATCO Pharma Limited | 25.73 Billion INR | 59.486% |
| Piramal Pharma Limited | 24.47 Billion INR | 57.391% |
| Sigachi Industries Limited | 2 Billion INR | -420.745% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -1110.728% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 95.966% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -152.876% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -1006.409% |
| Themis Medicare Limited | 1.5 Billion INR | -593.315% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 77.7% |
| Valiant Laboratories Limited | -60.66 Million INR | 17287.772% |
| Wanbury Limited | 1.73 Billion INR | -502.481% |
| Windlas Biotech Limited | 1.33 Billion INR | -678.816% |
| ZIM Laboratories Limited | 1.26 Billion INR | -723.024% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 91.673% |
| Ajanta Pharma Limited | 21.06 Billion INR | 50.499% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | -68.327% |
| Achyut Healthcare Limited | 4.86 Million INR | -214398.869% |
| Lasa Supergenerics Limited | 121.02 Million INR | -8515.046% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 1830.858% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -78.806% |
| Alpa Laboratories Limited | 188.89 Million INR | -5419.887% |
| Gufic Biosciences Limited | 4.16 Billion INR | -150.181% |
| Ind-Swift Limited | 2.17 Billion INR | -379.937% |
| Indoco Remedies Limited | 6.04 Billion INR | -72.591% |
| Hester Biosciences Limited | 1.27 Billion INR | -718.654% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -182.153% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -608.435% |
| RPG Life Sciences Limited | 2.48 Billion INR | -319.927% |
| Mankind Pharma Limited | 44.52 Billion INR | 76.58% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 84.963% |
| Unichem Laboratories Limited | 4.86 Billion INR | -114.326% |
| Bal Pharma Limited | 770.19 Million INR | -1253.786% |
| Strides Pharma Science Limited | 14.38 Billion INR | 27.532% |
| Venus Remedies Limited | 2.18 Billion INR | -377.727% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 46.919% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 93.627% |
| Divi's Laboratories Limited | 32.44 Billion INR | 67.858% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -250.827% |
| Shilpa Medicare Limited | 3.54 Billion INR | -193.972% |
| Aarti Drugs Limited | 8.31 Billion INR | -25.379% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -127.619% |
| Suven Life Sciences Limited | -200.79 Million INR | 5292.702% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 54.067% |
| Hikal Limited | 3.14 Billion INR | -231.738% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -80.351% |
| Sequent Scientific Limited | 2.97 Billion INR | -250.041% |
| Novartis India Limited | 1.32 Billion INR | -685.801% |
| Granules India Limited | 16.79 Billion INR | 37.933% |
| Wockhardt Limited | 16.24 Billion INR | 35.796% |
| Brooks Laboratories Limited | 65.62 Million INR | -15789.653% |
| Neuland Laboratories Limited | 8.24 Billion INR | -26.418% |
| Morepen Laboratories Limited | 6.16 Billion INR | -69.231% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -1580.447% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -1381.91% |